Evidence map›Paper›PMID 41844923›Full record

ArticleNPJ precision oncology2026

Computational pathology features of immune architecture predict clinically relevant outcomes in small-cell lung cancer (SCLC).

Cristian Barrera, Prantesh Jain, Germán Corredor, Tanmoy Dam, Himanshu Maurya, Tilak Pathak, Boulos Beshai, Stuthi Perimbeti, Jaishree Jagirdar, Kristin Higgins and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Cristian Barrera *Emory University, Atlanta, GA, USA.
Prantesh Jain *Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Germán CorredorEmory University, Atlanta, GA, USA.
Tanmoy DamEmory University, Atlanta, GA, USA.
Himanshu MauryaEmory University, Atlanta, GA, USA.
Tilak PathakEmory University, Atlanta, GA, USA.
Boulos BeshaiRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Stuthi PerimbetiPenn State Cancer Institute, Hershey, PA, USA.
Jaishree JagirdarDivision of Cardiothoracic Pathology, Emory University, Atlanta, GA, USA.
Kristin HigginsCity of Hope National Medical Center, Atlanta, GA, USA.
Afshin DowlatiUniversity Hospitals, Case Western Reserve University, Cleveland, OH, USA.
Anant MadabhushiEmory University, Atlanta, GA, USA. anantm@emory.edu.

Funding

P-CARRS-BRAIN: Multi-domain (genetic, socio-behavioral, vascular) risk factors and prediction of Alzheimer’s Disease continuum in South Asians in IndiaR01AG089759 · NIA · EMORY UNIVERSITY · PI Suvarna Alladi, ALLAN I LEVEY · 2024 to 2026
$12.8M
Computational Pathology of Proteinuric DiseasesR01DK118431 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI BARISONI, LAURA MARIACHIARA, HODGIN, JEFFREY BENTON · 2018 to 2025
$3.6M
Imaging signatures of early tuberculosisR01AI175555 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Yingda Linda Xie · 2024 to 2026
$2.0M
Biomedical Laboratory Research and Development, VA Office of Research and Development I01CX002622, I01CX002776, IK6BX006185BLRD VA IK6 BX006185Kidney Mapping and Atlas Project (KMAP) U01 DK133090 - 01NCI NIH HHS R01 CA249992 - 01A1 R01 CA216579 - 01A1 R01 CA257612 - 01A1 R01 CA264017 - 01 R01 CA268287 - 01A1 U01 CA113913 - 16A1 U01 CA239055 - 01 U01 CA269181 - 01 U24 CA274494 - 01 U54 CA254566 - 01NHLBI NIH HHS R01 HL151277 - 01A1 R01 HL158071 - 01A1NIAID NIH HHS R01 AI175555NIA NIH HHS R01 AG089759NIDCR NIH HHS R21 DE032344 - 01NIDDK NIH HHS R01 DK118431Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Cancer Research Program W81XWH-16-1-0329Office of the Assistant Secretary of Defense for Health Affairs through the Prostate Cancer Research Program W81XWH-15-1-0558, W81XWH-20-1-0851, W81XWH-21-1-0160United States Department of Veterans Affairs VA Merit Review IBX004121U.S. National Library of Medicine R01 LM013864 - 01A1VA Research and Development Office through the Lung Precision Oncology Program LPOP-L0021
6 · The paper itself

Abstract

First-line treatment for small-cell lung cancer (SCLC) involves platinum-based chemotherapy and immunotherapy for extensive (ES) and limited (LM) disease, respectively. Rapid progression and metastasis highlight the need for improved biomarkers. We developed PhenopyCell, a computational pathology tool that quantifies immune-tumor spatial architecture on Hematoxylin and Eosin (H&E) slides to predict outcomes. Developing PhenopyCell for spatial quantification of immune-tumor interactions and clinical outcome prediction. Retrospective study of 281 SCLC patients (149 LM, 132 ES) treated with platinum chemotherapy (2010-2020) from multi-institutional archives, divided into training (D1, n = 101) and validation (D2/D3, n = 180) cohorts. PhenopyCell extracted 101 spatial features (immune clustering, tumor density) from whole-slide images. Overall survival (OS) via Cox models and chemotherapy response through ROC and precision-recall analyses. PhenopyCell-derived features correlated with OS and treatment response across datasets (D

Identifiers

PMID41844923
PMCPMC12996542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.